This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
REGNPositive Net Change IONSPositive Net Change NTLAPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-editing genomics pharmaceuticals
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy
by Zacks Equity Research
Ultragenyx submits a BLA to the FDA seeking the accelerated approval of UX111 for patients with Sanfilippo syndrome type A in the United States.
RAREPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs gene-editing gene-therapy medical pharmaceuticals
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List
by Zacks Equity Research
Eli Lilly stock gains as the FDA removes tirzepatide drugs from the drug shortage list following a thorough reevaluation.
NVOPositive Net Change LLYPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam
by Zacks Equity Research
Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.
ALNYPositive Net Change EXELNegative Net Change SRPTPositive Net Change ADMANegative Net Change
biotechnology
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.
ALNYPositive Net Change EXELNegative Net Change SRPTPositive Net Change ADMANegative Net Change
biotechnology biotechs gene-therapy immuno-therapy medical pharmaceuticals
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
by Zacks Equity Research
Krystal Biotech reports initial data from a phase I/II study showing therapeutic benefit in NSCLC patients treated with its immunotherapy candidate, KB707.
CTMXPositive Net Change SPRONegative Net Change KRYSPositive Net Change CSTLPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
ReNew Energy Global PLC (RNW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RNWPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
by Zacks Equity Research
Enzo Biochem reports a first-quarter fiscal 2025 quarterly loss and revenue drop across regions amid challenges in the life sciences tools market.
biotechnology biotechs earnings medical
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
by Zacks Equity Research
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
REGNPositive Net Change BAYRYPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
by Zacks Equity Research
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell lung cancer indication.
GILDNegative Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
by Zacks Equity Research
GILD and GSK are in the spotlight in the biotech sector with quite a few regulatory and pipeline updates.
REGNPositive Net Change GSKNegative Net Change GILDNegative Net Change ANABPositive Net Change EWTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
by Zacks Equity Research
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
NVOPositive Net Change LLYPositive Net Change CTLTPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
by Ekta Bagri
We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.
SRPTPositive Net Change VYGRPositive Net Change CRSPPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Should You Buy VinFast Auto Ltd. (VFS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VFSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD Obtains Positive CHMP Opinion for Liver Disease Drug
by Zacks Equity Research
The CHMP recommends the approval of Gilead's seladelpar in combination with ursodeoxycholic acid for the treatment of primary biliary cholangitis in adults.
GSKNegative Net Change GILDNegative Net Change MRUSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
REGNPositive Net Change RHHBYPositive Net Change BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
by Zacks Equity Research
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
EDITNegative Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs crispr gene-editing gene-therapy medical pharmaceuticals
ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline
by Zacks Equity Research
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
ABBVPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Regeneron Down 15.5% Year to Date: How to Play the Stock?
by Ekta Bagri
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
by Zacks Equity Research
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
NVOPositive Net Change CTMXPositive Net Change SPRONegative Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
by Zacks Equity Research
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
BMYPositive Net Change PFEPositive Net Change GILDNegative Net Change CADLNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Should You Buy Pactiv Evergreen Inc. (PTVE) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
by Zacks Equity Research
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
GSKNegative Net Change ANABPositive Net Change CSTLPositive Net Change IMCRPositive Net Change
biotechnology biotechs pharmaceuticals
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
by Zacks Equity Research
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change CRDFNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
by Zacks Equity Research
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
ALNYPositive Net Change PFEPositive Net Change GILDNegative Net Change QUREPositive Net Change
biotechnology biotechs dna-sequencing gene-editing gene-therapy medical pharmaceuticals